Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Prasterone | The risk or severity of adverse effects can be increased when Prasterone is combined with Epimestrol. |
| Exemestane | The therapeutic efficacy of Exemestane can be decreased when used in combination with Epimestrol. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Epimestrol. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Epimestrol. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Epimestrol. |
| Lenalidomide | Epimestrol may increase the thrombogenic activities of Lenalidomide. |
| Ospemifene | The risk or severity of adverse effects can be increased when Epimestrol is combined with Ospemifene. |
| Ropinirole | Epimestrol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy. |
| Thalidomide | Epimestrol may increase the thrombogenic activities of Thalidomide. |
| Cetuximab | Epimestrol may increase the thrombogenic activities of Cetuximab. |
| Human immunoglobulin G | Epimestrol may increase the thrombogenic activities of Human immunoglobulin G. |
| Omalizumab | Epimestrol may increase the thrombogenic activities of Omalizumab. |
| Adalimumab | Epimestrol may increase the thrombogenic activities of Adalimumab. |
| Gemtuzumab ozogamicin | Epimestrol may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Indium In-111 satumomab pendetide | Epimestrol may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Infliximab | Epimestrol may increase the thrombogenic activities of Infliximab. |
| Trastuzumab | Epimestrol may increase the thrombogenic activities of Trastuzumab. |
| Rituximab | Epimestrol may increase the thrombogenic activities of Rituximab. |
| Basiliximab | Epimestrol may increase the thrombogenic activities of Basiliximab. |
| Muromonab | Epimestrol may increase the thrombogenic activities of Muromonab. |
| Digoxin Immune Fab (Ovine) | Epimestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Ibritumomab tiuxetan | Epimestrol may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Tositumomab | Epimestrol may increase the thrombogenic activities of Tositumomab. |
| Alemtuzumab | Epimestrol may increase the thrombogenic activities of Alemtuzumab. |
| Capromab pendetide | Epimestrol may increase the thrombogenic activities of Capromab pendetide. |
| Efalizumab | Epimestrol may increase the thrombogenic activities of Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | Epimestrol may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit). |
| Natalizumab | Epimestrol may increase the thrombogenic activities of Natalizumab. |
| Palivizumab | Epimestrol may increase the thrombogenic activities of Palivizumab. |
| Daclizumab | Epimestrol may increase the thrombogenic activities of Daclizumab. |
| Bevacizumab | Epimestrol may increase the thrombogenic activities of Bevacizumab. |
| Technetium Tc-99m arcitumomab | Epimestrol may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Eculizumab | Epimestrol may increase the thrombogenic activities of Eculizumab. |
| Panitumumab | Epimestrol may increase the thrombogenic activities of Panitumumab. |
| Ranibizumab | Epimestrol may increase the thrombogenic activities of Ranibizumab. |
| Galiximab | Epimestrol may increase the thrombogenic activities of Galiximab. |
| Pexelizumab | Epimestrol may increase the thrombogenic activities of Pexelizumab. |
| Afelimomab | Epimestrol may increase the thrombogenic activities of Afelimomab. |
| Epratuzumab | Epimestrol may increase the thrombogenic activities of Epratuzumab. |
| Bectumomab | Epimestrol may increase the thrombogenic activities of Bectumomab. |
| Oregovomab | Epimestrol may increase the thrombogenic activities of Oregovomab. |
| IGN311 | Epimestrol may increase the thrombogenic activities of IGN311. |
| Adecatumumab | Epimestrol may increase the thrombogenic activities of Adecatumumab. |
| Labetuzumab | Epimestrol may increase the thrombogenic activities of Labetuzumab. |
| Matuzumab | Epimestrol may increase the thrombogenic activities of Matuzumab. |
| Fontolizumab | Epimestrol may increase the thrombogenic activities of Fontolizumab. |
| Bavituximab | Epimestrol may increase the thrombogenic activities of Bavituximab. |
| CR002 | Epimestrol may increase the thrombogenic activities of CR002. |
| Rozrolimupab | Epimestrol may increase the thrombogenic activities of Rozrolimupab. |
| Girentuximab | Epimestrol may increase the thrombogenic activities of Girentuximab. |
| Obiltoxaximab | Epimestrol may increase the thrombogenic activities of Obiltoxaximab. |
| XTL-001 | Epimestrol may increase the thrombogenic activities of XTL-001. |
| NAV 1800 | Epimestrol may increase the thrombogenic activities of NAV 1800. |
| Briakinumab | Epimestrol may increase the thrombogenic activities of Briakinumab. |
| Otelixizumab | Epimestrol may increase the thrombogenic activities of Otelixizumab. |
| AMG 108 | Epimestrol may increase the thrombogenic activities of AMG 108. |
| Iratumumab | Epimestrol may increase the thrombogenic activities of Iratumumab. |
| Enokizumab | Epimestrol may increase the thrombogenic activities of Enokizumab. |
| Ramucirumab | Epimestrol may increase the thrombogenic activities of Ramucirumab. |
| Farletuzumab | Epimestrol may increase the thrombogenic activities of Farletuzumab. |
| Veltuzumab | Epimestrol may increase the thrombogenic activities of Veltuzumab. |
| Ustekinumab | Epimestrol may increase the thrombogenic activities of Ustekinumab. |
| Trastuzumab emtansine | Epimestrol may increase the thrombogenic activities of Trastuzumab emtansine. |
| PRO-542 | Epimestrol may increase the thrombogenic activities of PRO-542. |
| TNX-901 | Epimestrol may increase the thrombogenic activities of TNX-901. |
| Inotuzumab ozogamicin | Epimestrol may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| RI 624 | Epimestrol may increase the thrombogenic activities of RI 624. |
| Stamulumab | Epimestrol may increase the thrombogenic activities of MYO-029. |
| CT-011 | Epimestrol may increase the thrombogenic activities of CT-011. |
| Leronlimab | Epimestrol may increase the thrombogenic activities of Leronlimab. |
| Glembatumumab vedotin | Epimestrol may increase the thrombogenic activities of Glembatumumab vedotin. |
| Olaratumab | Epimestrol may increase the thrombogenic activities of Olaratumab. |
| IPH 2101 | Epimestrol may increase the thrombogenic activities of IPH 2101. |
| TB-402 | Epimestrol may increase the thrombogenic activities of TB-402. |
| Caplacizumab | Epimestrol may increase the thrombogenic activities of Caplacizumab. |
| IMC-1C11 | Epimestrol may increase the thrombogenic activities of IMC-1C11. |
| Eldelumab | Epimestrol may increase the thrombogenic activities of Eldelumab. |
| Lumiliximab | Epimestrol may increase the thrombogenic activities of Lumiliximab. |
| Canakinumab | Epimestrol may increase the thrombogenic activities of Canakinumab. |
| Ipilimumab | Epimestrol may increase the thrombogenic activities of Ipilimumab. |
| Nimotuzumab | Epimestrol may increase the thrombogenic activities of Nimotuzumab. |
| Clenoliximab | Epimestrol may increase the thrombogenic activities of Clenoliximab. |
| Tocilizumab | Epimestrol may increase the thrombogenic activities of Tocilizumab. |
| BIIB015 | Epimestrol may increase the thrombogenic activities of BIIB015. |
| Sonepcizumab | Epimestrol may increase the thrombogenic activities of Sonepcizumab. |
| Motavizumab | Epimestrol may increase the thrombogenic activities of Motavizumab. |
| Elotuzumab | Epimestrol may increase the thrombogenic activities of Elotuzumab. |
| AVE9633 | Epimestrol may increase the thrombogenic activities of AVE9633. |
| Carotuximab | Epimestrol may increase the thrombogenic activities of Carotuximab. |
| XmAb 2513 | Epimestrol may increase the thrombogenic activities of XmAb 2513. |
| Coltuximab ravtansine | Epimestrol may increase the thrombogenic activities of Coltuximab ravtansine. |
| Lucatumumab | Epimestrol may increase the thrombogenic activities of Lucatumumab. |
| Pertuzumab | Epimestrol may increase the thrombogenic activities of Pertuzumab. |
| Siplizumab | Epimestrol may increase the thrombogenic activities of Siplizumab. |
| Apolizumab | Epimestrol may increase the thrombogenic activities of Apolizumab. |
| Sibrotuzumab | Epimestrol may increase the thrombogenic activities of Sibrotuzumab. |
| Bivatuzumab | Epimestrol may increase the thrombogenic activities of Bivatuzumab. |
| Lerdelimumab | Epimestrol may increase the thrombogenic activities of Lerdelimumab. |
| Lexatumumab | Epimestrol may increase the thrombogenic activities of Lexatumumab. |
| Reslizumab | Epimestrol may increase the thrombogenic activities of Reslizumab. |